$3.38-0.15 (-4.25%)
Beyond Air, Inc.
Beyond Air, Inc. in the Healthcare sector is trading at $3.38 with a market capitalization of $3M. Wall Street consensus targets $20.00 (2 analysts), implying a +491.7% move over the next 12 months. The stock is currently near its 52-week low of $3.32, remaining 76.1% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.77Mβ | $1.91Mβ | $2.19Mβ | $1.82Mβ | $1.76M |
| Gross Profit | $225,000β | $94,000β | $300,000β | -$298,000β | $156,000 |
| Operating Income | -$6.61Mβ | -$7.17Mβ | -$6.60Mβ | -$7.66Mβ | -$7.62M |
| Net Income | -$7.93Mβ | -$10.28Mβ | -$7.34Mβ | -$7.94Mβ | -$7.69M |
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension o...

FDA approval decision looms for next-gen device as revenue guidance projects 110% growth.
Beyond Air Inc (XAIR) reports flat Q1 revenue but secures $30 million financing, expands global reach, and reaffirms ambitious 2027 growth targets amid FDA review progress.

Moby summary of Beyond Air, Inc.'s Q1 2027 earnings call
Moby summary of Beyond Air, Inc.'s Q4 2026 earnings call
New hospital deals and a next-gen device drive Beyond Air's commercial strategy shift.